Bioworld Technology CO., Ltd.



DREAM (G59) Peptide

Cat No.: BS1727P

Background

DRE is a regulatory sequence that silences basal transcription and is localized to the promoter region of the gene encoding human prodynorphin, an opioid peptide involved in memory acquisition and pain. DREAM forms functional homotetramers that are required for the interaction with the DRE. This association is highly influenced by calcium, as an increase in Ca2+- directly inhibits DREAM binding and thereby blocks the repressor activity of DREAM. DREAM transcripts are detected in brain, thymus and thyroid gland, and it is expressed as a nuclear protein. DREAM has been shown to inhibit transcription of other proteins containing DRE-like motifs, including the gene encoding for the AP-1 transcription factor c-Fos, suggesting that DREAM may influence a wide variety of cellular genes.

Swiss-Prot

Q9Y2W7

Applications

Blocking

Specificity

This peptide can be used with studies using BS1727 DREAM (G59) pAb.

Purification & Purity

Synthetic peptide DREAM (G59). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at $4 \, \mathbb{C}$ short term. Aliquot and store at $-20 \, \mathbb{C}$ long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.